Experimentally proven targets of miR-146a include complement factor H (CFH), interleukin-1 receptor-associated kinase-1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6), all associated with innate immunity and inflammatory pathways which are dysregulated in Alzheimer's disease (Wang et al., 2012). Here, TRAF6 is linked to early-onset autosomal dominant Alzheimer disease.